Dr. Maria Baer, MD

• Hematology

• Internal Medicine

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Vanderbilt University

  Medical School, 1985

• English

• French

• The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms, 2012-12-19

• FLT3 inhibitors in acute myeloid leukemia: Current status and future directions, 2017-04-20

• PP2A-activating drugs enhance FLT3 inhibitor efficacy through AKT inhibition-dependent GSK-3ß-mediated c-Myc and Pim-1 proteasomal degradation, 2021-02-10

• Phase I dose escalation study of lestaurtinib in patients with myelofibrosis, 2015-02-20

• Impact of IDH1 c.315C>T SNP on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study, 2022-03-18

• Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial, 2020-10-26

• A phase 2 study incorporating sorafenib into the chemotherapy for older adults withFLT3-mutated acute myeloid leukemia: CALGB 11001, 2017-01-24

• Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines, 2013-03-21

• Prognostic and biologic significance ofDNMT3Bexpression in older patients with cytogenetically normal primary acute myeloid leukemia, 2014-09-10

• Chronic myeloid leukemia presenting as an atraumatic splenic rupture in the setting of coronavirus disease 2019 infection, 2023-04-28

• Therapeutic Targeting ofTP53-mutated Acute Myeloid Leukemia by Inhibiting HIF-1a with Echinomycin, 2020-02-15

• Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic Syndromes, 2013-08-06

• Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias, 2013-08-15

• Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2, 2016-01-19

• Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8, 2014-03-21

• GAS6expression identifies high-risk adult AML patients: potential implications for therapy, 2013-12-11

• Role of Breast Cancer Resistance Protein (BCRP/ABCG2) in Cancer Drug Resistance, 2012-01-11

• Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia, 2020-02-16

• Mutations in theCCND1andCCND2genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia, 2016-11-15

• Results of a Randomized Phase 3 Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia ("SEAMLESS”), 2021-08-23

• Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication, 2013-09-05

• Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation., 2019-04-09

• The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions, 2013-08-14

• Phase I Study Of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma, 2009-08-11

• Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study, 2022-03-31

• Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: report of CALGB 361006 (Alliance), 2019-10-24